Phase II Evaluation of 24-h Continuous Infusion Topotecan in Recurrent, Potentially Platinum-Sensitive Ovarian Cancer: A Gynecologic Oncology Group Study

Gynecologic Oncology ◽

10.1006/gyno.2000.5755 ◽

2000 ◽

Vol 77 (1) ◽

pp. 112-115 ◽

Author(s):

Maurie Markman ◽

John A. Blessing ◽

Ronald D. Alvarez ◽

Parviz Hanjani ◽

Steven Waggoner ◽

...

Keyword(s):

Ovarian Cancer ◽

Continuous Infusion ◽

Phase Ii ◽

Gynecologic Oncology ◽

Gynecologic Oncology Group ◽

Oncology Group ◽

Oncology Group Study ◽

Platinum Sensitive

Download Full-text

Phase II Trial of Pyrazoloacridine in Recurrent Platinum-Sensitive Ovarian Cancer: A Gynecologic Oncology Group Study

Gynecologic Oncology ◽

10.1006/gyno.2001.6441 ◽

2002 ◽

Vol 84 (1) ◽

pp. 32-35 ◽

Author(s):

Steven C. Plaxe ◽

John A. Blessing ◽

Michael A. Bookman ◽

William T. Creasman

Keyword(s):

Ovarian Cancer ◽

Phase Ii ◽

Phase Ii Trial ◽

Gynecologic Oncology ◽

Gynecologic Oncology Group ◽

Oncology Group ◽

Oncology Group Study ◽

Platinum Sensitive

Download Full-text

A phase II evaluation of tirapazamine plus cisplatin in the treatment of recurrent platinum-sensitive ovarian or primary peritoneal cancer: A Gynecologic Oncology Group study

Gynecologic Oncology ◽

10.1016/j.ygyno.2005.09.032 ◽

2006 ◽

Vol 100 (3) ◽

pp. 586-590 ◽

Author(s):

Allan Covens ◽

John Blessing ◽

David Bender ◽

Robert Mannel ◽

Mark Morgan

Keyword(s):

Phase Ii ◽

Gynecologic Oncology ◽

Gynecologic Oncology Group ◽

Oncology Group ◽

Oncology Group Study ◽

Primary Peritoneal Cancer ◽

Peritoneal Cancer ◽

Platinum Sensitive

Download Full-text

A phase II study of neoadjuvant chemotherapy plus durvalumab and tremelimumab in advanced-stage ovarian cancer: a Korean Gynecologic Oncology Group Study (KGOG 3046), TRU-D

Journal of Gynecologic Oncology ◽

10.3802/jgo.2019.30.e112 ◽

2019 ◽

Vol 30 (6) ◽

Author(s):

Jung-Yun Lee ◽

Jae Weon Kim ◽

Myong Cheol Lim ◽

Sunghoon Kim ◽

Hee Seung Kim ◽

...

Keyword(s):

Ovarian Cancer ◽

Neoadjuvant Chemotherapy ◽

Phase Ii ◽

Phase Ii Study ◽

Gynecologic Oncology ◽

Gynecologic Oncology Group ◽

Advanced Stage ◽

Oncology Group ◽

Oncology Group Study

Download Full-text

A phase II study of two topotecan regimens evaluated in recurrent platinum-sensitive ovarian, fallopian tube or primary peritoneal cancer: A Gynecologic Oncology Group Study (GOG 146Q)

Yearbook of Oncology ◽

10.1016/j.yonc.2011.07.016 ◽

2011 ◽

Vol 2011 ◽

pp. 74-75

Author(s):

J.T. Thigpen

Keyword(s):

Fallopian Tube ◽

Phase Ii ◽

Phase Ii Study ◽

Gynecologic Oncology ◽

Gynecologic Oncology Group ◽

Oncology Group ◽

Oncology Group Study ◽

Primary Peritoneal Cancer ◽

Peritoneal Cancer ◽

Platinum Sensitive

Download Full-text

A Phase II Trial of CI-958 in Recurrent Platinum-Sensitive Ovarian Carcinoma: A Gynecologic Oncology Group Study

Gynecologic Oncology ◽

10.1006/gyno.2001.6182 ◽

2001 ◽

Vol 81 (3) ◽

pp. 433-435 ◽

Author(s):

Mark A. Hoffman ◽

John A. Blessing ◽

Evelyn R. Nuñez

Keyword(s):

Ovarian Carcinoma ◽

Phase Ii ◽

Phase Ii Trial ◽

Gynecologic Oncology ◽

Gynecologic Oncology Group ◽

Oncology Group ◽

Oncology Group Study ◽

Platinum Sensitive

Download Full-text

Bevacizumab plus fosbretabulin in recurrent ovarian cancer: Overall survival and exploratory analyses of a randomized phase II NRG oncology/gynecologic oncology group study

Gynecologic Oncology ◽

10.1016/j.ygyno.2020.07.015 ◽

2020 ◽

Vol 159 (1) ◽

pp. 79-87

Author(s):

Krishnansu S. Tewari ◽

Michael W. Sill ◽

Robert L. Coleman ◽

Carol Aghajanian ◽

Robert Mannel ◽

...

Keyword(s):

Ovarian Cancer ◽

Overall Survival ◽

Phase Ii ◽

Gynecologic Oncology ◽

Recurrent Ovarian Cancer ◽

Gynecologic Oncology Group ◽

Oncology Group ◽

Oncology Group Study ◽

Randomized Phase Ii

Download Full-text

A phase II evaluation of bortezomib in the treatment of recurrent platinum-sensitive ovarian or primary peritoneal cancer: A Gynecologic Oncology Group study

Gynecologic Oncology ◽

10.1016/j.ygyno.2009.07.023 ◽

2009 ◽

Vol 115 (2) ◽

pp. 215-220 ◽

Author(s):

Carol Aghajanian ◽

John A. Blessing ◽

Kathleen M. Darcy ◽

Gary Reid ◽

Koen DeGeest ◽

...

Keyword(s):

Phase Ii ◽

Gynecologic Oncology ◽

Gynecologic Oncology Group ◽

Oncology Group ◽

Oncology Group Study ◽

Primary Peritoneal Cancer ◽

Peritoneal Cancer ◽

Platinum Sensitive

Download Full-text

A phase II study of two topotecan regimens evaluated in recurrent platinum-sensitive ovarian, fallopian tube or primary peritoneal cancer: a Gynecologic Oncology Group Study (GOG 146Q)

Yearbook of Medicine ◽

10.1016/s0084-3873(11)00207-0 ◽

2011 ◽

Vol 2011 ◽

pp. 154-155

Author(s):

J.T. Thigpen

Keyword(s):

Fallopian Tube ◽

Phase Ii ◽

Phase Ii Study ◽

Gynecologic Oncology ◽

Gynecologic Oncology Group ◽

Oncology Group ◽

Oncology Group Study ◽

Primary Peritoneal Cancer ◽

Peritoneal Cancer ◽

Platinum Sensitive

Download Full-text

A Phase II Trial of Didemnin B (NSC #335319) in Patients with Previously Treated Epithelial Ovarian Cancer A Gynecologic Oncology Group Study

American Journal of Clinical Oncology ◽

10.1097/00000421-199302000-00012 ◽

1993 ◽

Vol 16 (1) ◽

pp. 47-49 ◽

Author(s):

John H. Malfetano ◽

John A. Blessing ◽

Allan J. Jacobs

Keyword(s):

Ovarian Cancer ◽

Epithelial Ovarian Cancer ◽

Phase Ii ◽

Phase Ii Trial ◽

Gynecologic Oncology ◽

Gynecologic Oncology Group ◽

Oncology Group ◽

Oncology Group Study ◽

Previously Treated

Download Full-text

A Phase II Study of Fazarabine in Patients with Advanced Ovarian Cancer A Gynecologic Oncology Group Study

American Journal of Clinical Oncology ◽

10.1097/00000421-199504000-00012 ◽

1995 ◽

Vol 18 (2) ◽

pp. 156-157 ◽

Author(s):

Alberto Manetta ◽

John A. Blessing ◽

Katherine Y. Look

Keyword(s):

Ovarian Cancer ◽

Phase Ii ◽

Phase Ii Study ◽

Gynecologic Oncology ◽

Advanced Ovarian Cancer ◽

Gynecologic Oncology Group ◽

Oncology Group ◽

Oncology Group Study

Download Full-text